Diagnostics

Imaging Agents to Monitor the Distribution of Therapies Delivered to the Brain
Background: The National Institute of Neurological Disorders and Stroke (NINDS) seeks a commercial collaborator to work with NINDS in the development and commercialization of surrogate markers for monitoring the spatial distribution of therapeutic substances by (more...)
(Full Text)

Anakin Protein as a Prognostic Tool for Diagnosing Breast Cancer Outcome
Available for collaborative research toward commercial development and/or exclusive and non-exclusive licensing: Method of diagnosis for early metastasis and therapeutic inhibition of metastasis. Nucleic acid sequence of Anakin protein, an extracellular matrix (ECM) modifier gene. SiRNA sequences (more...)
(Full Text)

Bioinformatic Tools for Genomic DNA Sequence Dimorphisms (Indels)
Background: The National Cancer Institute, Center for Cancer Research, Mouse Cancer Genetics Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize identification and use (more...)
(Full Text)

Identification of T-Cell Receptors (TCR)
Background: The NIH National Cancer Institute's Surgery Branch seeks a research partner to further develop, evaluate, or commercialize adoptive immunotherapy therapeutics under a Collaboration Agreement or a Cooperative Research and Development Agreement (CRADA). Technology: Adoptive immunotherapy circumvents a (more...)
(Full Text)

Diagnosis and Therapeutic Monitoring of Cancer Using Beta-Catenin Splice Variants
Background: The National Cancer Institute, Division of Cancer Epidemiology and Genetics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a method of diagnosing or (more...)
(Full Text)

Method for Predicting and Detecting Tumor Metastasis
Background: The National Institute of Child Health and Human Development's Laboratory of Development Neurobiology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods (more...)
(Full Text)

Inhibitors for Metastasized Breast Cancers
Background: The National Cancer Institute's Laboratory of Molecular Pharmacology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize histone deacetylase (HDAC) inhibitor (HDI) for breast (more...)
(Full Text)

Methods of Glycosylation and Bioconjugation
Background: The National Cancer Institute's Structural Glycobiology Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, and/or commercialize methods of glycosylation and bioconjugation that can be (more...)
(Full Text)

Selenocysteine Enables a New Platform for Immunoconjugates
The Experimental Transplantation and Immunology Branch of the National Cancer Institute is seeking statements of capability or interest from parties interested in forming a collaborative research alliance to further develop, evaluate, or commercialize a new platform technology (more...)
(Full Text)

Nanoantibodies as Therapeutics and Diagnostics
Background: The National Cancer Institute Center for Cancer Research Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize nanoantibodies as therapeutics or diagnostics. The (more...)
(Full Text)

Human Monoclonal Antibody Against Mesothelin
Background: The National Cancer Institute's Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize human antibodies that act against mesothelin. NIH inventors have demonstrated (more...)
(Full Text)

Methods and Compositions for the Diagnosis of Neuroendocrine Lung Cancer
Background: The National Cancer Institute's Laboratory of Human Carcinogenesis is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods for the diagnosis of neuroendocrine lung (more...)
(Full Text)

Molecular Diagnostics for Breast Cancer Precursors
Background: The National Cancer Institute, Genetics Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a method of profiling ductal carcinoma of the breast. The (more...)
(Full Text)

Optical Cells with Biological Applications
Background: NICHD is seeking statements of capability or interest from parties interested in collaborative research and/or partnership agreements to develop, evaluate, or commercialize optical cells with tissue pathology diagnostic applications. Apart from pathology diagnostics, potential applications (more...)
(Full Text)

Cell Lines For Angiogenesis Screening
Background: The National Cancer Institute's Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize multicolored fluorescent cell lines and software for high-throughput (more...)
(Full Text)

Cripto-1 as a Biomarker for Cardiac Ischemia
Description of Technology: This technology describes Cripto-1 as a biomarker for infarcted cardiac tissues. Cripto-1 is a member of the epidermal growth factor (EGF)-related proteins and is currently thought to play an important role (more...)
(Full Text)

Sugar Substrates For Targeted-Drug Delivery
Background: The National Cancer Institute's Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the synthesis of UDP derivatives of C2 modified galactose (more...)
(Full Text)

Biomarkers For Birt-Hogg-Dube (BHD) Syndrome And Renal Cancer
Background: The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize detection methods to screen a biomarker for (more...)
(Full Text)

Antibody-Based Cancer Biomarkers And Therapeutic Agents
Background: The National Cancer Institute's Mammary Biology and Tumorigenesis Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize isoform-specifc antibodies to the human prolactin (more...)
(Full Text)

Personalized Medicine Approach To Assessing Cancer Prevention Properties Of Statins
Background: The National Cancer Institute's Chemopreventive Agent Development Research Group is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods to assess reduction of (more...)
(Full Text)

Metabolic Biomarkers To Detect Exposure To Gamma Radiation
Background:  The National Cancer Institute's Laboratory of Metabolism is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the development of biomarkers for radiation exposure and (more...)
(Full Text)

cDNA Fragments As Novel Anti-Cancer Therapeutics And Diagnostics
Background: The National Cancer Institute's Hatfield Clinical Research Center is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize cDNA fragments as antiangiogenic and antitumor therapy. Technology: This (more...)
(Full Text)

Method For Detection Of Cancer Based On Spatial Genome Organization In The Cell Nucleus
Background: The National Cancer Institute's Cell Biology of Genomes Group is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize diagnostic methods for detection of (more...)
(Full Text)

Methods For Accurately Measuring And Regulating Adrenomedullin
Background: The National Cancer Institute's Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods to detect or regulate adrenomedullin (AM) levels. (more...)
(Full Text)

A Simple Genetic Test For Kidney Disease
Background: The National Cancer Institute's Laboratory of Genomic Diversity is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize genetic testing for kidney disease. Technology: An estimated (more...)
(Full Text)